Kiadis Pharma and The Leukemia & Lymphoma Society enter part­ner­ship for the devel­op­ment of ATIR101™ in ALL and AML patients

~ LLS will fund the Phase II devel­op­ment via an equi­ty invest­ment in Kiadis Pharma ~

Amsterdam, The Netherlands, February 1, 2016 – Kiadis Pharma N.V. (“Kiadis Pharma” or the “Company”) (Euronext Amsterdam and Brussels: KDS), a clin­i­cal stage bio­phar­ma­ceu­ti­cal com­pa­ny devel­op­ing inno­v­a­tive T-cell immunother­a­py treat­ments for blood can­cers and inher­it­ed blood dis­or­ders, today announces that it has entered into a part­ner­ship with The Leukemia & Lymphoma Society (LLS) under which LLS will fund the Phase II devel­op­ment of Kiadis Pharma’s lead prod­uct, ATIR101™, through an equi­ty invest­ment of approx­i­mate­ly $1 mil­lion.
LLS is invest­ing via its Therapy Acceleration Program (TAP), a strate­gic ini­tia­tive to part­ner direct­ly with biotech­nol­o­gy com­pa­nies to help accel­er­ate the devel­op­ment of promis­ing ther­a­pies, and the funds will be used to finance Kiadis Pharma’s sec­ond ongo­ing Phase II tri­al in leukemia patients. The Company intends to con­tin­ue this tri­al into a ran­dom­ized con­trolled Phase III piv­otal study that is planned to start lat­er this year. This ongo­ing Phase II tri­al is inves­ti­gat­ing the repeat­ed dos­ing of ATIR101™ as an adjunc­tive treat­ment to a T-cell deplet­ed hap­loiden­ti­cal hematopoi­et­ic stem cell trans­plan­ta­tion (HSCT) (donor cells from a half-matched relat­ed donor) in adult patients with acute myeloid leukemia (AML) or acute lym­phoblas­tic leukemia (ALL). The tri­al (CR-AIR-008; NCT02500550 / EudraCT 2015-002821-20) is con­duct­ed under an IND of the United States Food and Drug Administration and is set up to enroll patients in the United States as well as oth­er coun­tries, includ­ing Canada, Belgium and the United Kingdom.

Manfred Rüdiger, PhD, Chief Executive Officer of Kiadis Pharma, com­ment­ed: “We are pleased to be part­ner­ing with the world’s largest vol­un­tary health agency focused on blood can­cers. We see this as anoth­er val­i­da­tion of our inno­v­a­tive prod­uct can­di­date ATIR101™. The exten­sive net­work and exper­tise of The Leukemia & Lymphoma Society will be extreme­ly valu­able to us as we pre­pare to set up the piv­otal Phase III study lat­er this year. The fact that LLS is invest­ing into Kiadis Pharma with equi­ty is also a strong sign of con­fi­dence in what we do and our goal remains to be to bring this impor­tant prod­uct to patients as quick­ly as pos­si­ble.

Louis J. DeGennaro, Ph.D., LLS’s President and CEO, added: Stem cell trans­plan­ta­tion is one of the most effec­tive cura­tive treat­ments for blood can­cer patients, but it comes with great risk of life-threat­en­ing infec­tion and graft ver­sus host dis­ease (GVHD). Kiadis Pharma’s ATIR101™ shows promise in fight­ing these infec­tions by boost­ing the patient’s immune sys­tem whilst also reduc­ing GVHD. LLS is enthu­si­as­tic about sup­port­ing this pro­gram which we hope will improve out­comes for patients with blood can­cers.

Leave a Reply

Your email address will not be published. Required fields are marked *